Tracer library / [64Cu]CuCl2

[64Cu]CuCl2

Also written as [64Cu]CuCl2
Radionuclide
Cu-64
Modality
—
Production route
—
Stage
Clinical research
Syntheses indexed
1
Bladder cancerBrain metastasesGlioma and brain tumoursHepatobiliary and pancreatic cancerLung cancerMelanomaProstate cancerDosimetry and biodistribution studies

What it is

Compound class
Radiometal starting material
Target / mechanism
human copper transporter 1 (hCtr1) PMID 35464672
Clinical application
PET imaging of prostate cancer, bladder cancer, glioblastoma multiforme (GBM), and non-small cell lung carcinoma; potential for hepatocellular carcinoma, melanoma, and intracranial metastases PMID 35464672
Theranostic pair
—

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Neptis Mosaic-LC
ORA
————68Zn38199184
2024 Nucl Med Biol
64Cu semi-automated purification was performed using a NEPTIS Mosaic-LC synthesis unit employing CU, TBP, and TK201 (TrisKem) resins.

Need this precursor?We can point you to suppliers for [64Cu]CuCl2, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 2 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 33026209, 35464672. Stage set/updated at stage 39 from PMID 35464672: '64CuCl2 was successfully used for PET imaging of prostate cancer, bladder cancer, glioblastoma multiforme (GBM), and non-small cell lung carcinoma in humans'.